Status:
UNKNOWN
Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19
Lead Sponsor:
KK Women's and Children's Hospital
Collaborating Sponsors:
Singapore General Hospital
National University Hospital, Singapore
Conditions:
COVID-19
Eligibility:
All Genders
21-65 years
Brief Summary
The overall objective of this project is to develop an emergent treatment protocol using adoptive T-cell therapy for the treatment of severe COVID-19. The central hypothesis is that SARS-CoV-2 specifi...
Detailed Description
A novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of Coronavirus Disease 2019 (COVID-19). Currently, no vaccine or specific treatment has been proven to be effective. W...
Eligibility Criteria
Inclusion
- Age 21 to 65
- Had a history of COVID-19 with documented positive test for SARS-CoV-2 in the past
- Has recovered from COVID-19 and is now suitable for blood donation, fulfilling all standard blood donor criteria
- Negative test for SARS-CoV-2 currently
Exclusion
- Do not meet the standard criteria for blood cell donation at National University Hospital or Singapore General Hospital.
Key Trial Info
Start Date :
April 14 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2022
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT04351659
Start Date
April 14 2020
End Date
September 1 2022
Last Update
March 31 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
National University Hospital
Singapore, Singapore
2
Singapore General Hospital
Singapore, Singapore